Lab-on-a-chip multiplexed electrochemical sensor enables simultaneous detection of SARS-CoV-2 RNA and host antibodies

Devora Najjar[1, 2, 4 #], Joshua Rainbow[1, 3 #], Sanjay Sharma Timilsina[1 #], Pawan Jolly[1 #], Helena de Puig[1, 2 #], Mohamed Yafia[1], Nolan Durr[1], Hani Sallum[1], Galit Alter[5], Jonathan Z. Li[6], Xu G. Yu[5, 6], David R. Walt[1, 7, 8], Joseph A. Paradiso[4], Pedro Estrela[3], James J. Collins[1, 2, 9 *] and Donald E. Ingber[1, 7, 10, 11 *]

[1]Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115, USA

[2]Institute for Medical Engineering and Science, Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA

[3]Centre for Biosensors, Bioelectronics and Biodevices (C3Bio) and Department of Electronic and Electrical Engineering, University of Bath, Bath BA2 7AY, UK

[4]MIT Media Lab, Massachusetts Institute of Technology, Cambridge, MA 02139, USA

[5]Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.

[6]Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA

[7]Harvard Medical School, Boston, MA 02115, USA

[8]Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA

[9]Infectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA

[10]Vascular Biology Program and Department of Surgery, Boston Children's Hospital, Boston, MA 02115, USA

[11]Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Boston, MA 02115, USA

*Co-corresponding authors. Email: don.ingber@wyss.harvard.edu (D.E.I.), jimjc@mit.edu (J.J.C.)

# These authors contributed equally

Keywords: Lab-on-a-chip, multiplexed, CRISPR, serology, antibody, electrochemical sensor, COVID-19, saliva, SARS-CoV-2, point-of-care.

Abstract

The current COVID-19 pandemic highlights the continued need for rapid, accurate, and cost-

effective point-of-care (POC) diagnostics that can accurately assess an individual's infection and

immunity status for SARS-CoV-2. As the virus continues to spread and vaccines become more

widely available, detecting viral RNA and serological biomarkers can provide critical insights into

the status of infectious, previously infectious, and vaccinated individuals over time. Here, we

describe an integrated, low-cost, 3D printed, lab-on-a-chip device that extracts, concentrates, and

amplifies viral RNA from unprocessed patient saliva and simultaneously detects RNA and multiple

host anti-SARS-CoV-2 antibodies via multiplexed electrochemical (EC) outputs in two hours. The

EC sensor platform enables single-molecule CRISPR/Cas-based molecular detection of SARS-CoV-

2 viral RNA as well as serological detection of antibodies against the three immunodominant SARS-

CoV-2 viral antigens. This study demonstrates that microfluidic EC sensors can enable multiplexed

POC diagnostics that perform on par with traditional laboratory-based techniques, enabling

cheaper and more widespread monitoring of infection and immunity over time.

The COVID-19 pandemic has highlighted the need for cost-effective diagnostics for SARS-CoV-2 RNA

as well as for detection of antibodies generated by the host in response to infection. This type of

multifunctional detection platform will be particularly useful for diagnosis of both acute and convalescent

infections, as well as for assessing patient immunization status following vaccination. The clinical

timeline of SARS-CoV-2 infection consists of an acute phase, when viral RNA is detectable in clinical

samples, such as saliva or nasopharyngeal swabs, followed by a convalescent phase when serology

biomarkers, such as IgG antibodies, are present in saliva and serum[1]. Therefore, simultaneous analysis of

these different biomarkers in clinical samples as the disease progresses could provide more accurate

results for disease monitoring and management.

Molecular (nucleic acid) diagnostics that detect the presence of viral RNA are key to detecting the virus

during the first 5 days of infection, with a viral load peak around day 4 (**Supplementary Fig. S1**)[2-4].

Following the first few days of infection, the host produces IgM, IgA, and IgG antibodies in a process

known as seroconversion. These antibodies often become stable after the first 6 days of seroconversion

and their titers can remain stable over months[5,6]. The presence of different antibody types varies during

infection[7] and correlates with disease severity[8,9]. In particular, extensive cohort studies in hospitalized

patients show that IgG antibodies against different viral proteins (e.g., nucleocapsid or spike proteins)

correlate with disease severity and outcomes. For example, antibodies against the spike (S) protein are

more specific[10] and correlate with virus neutralization[8], while antibodies against the nucleocapsid (N)

protein have longer clearance rates[11] and might appear earlier during infection[12]. Therefore, serological

assays that detect the host's antibodies developed after an infection can widen the testing window for

SARS-CoV-2 beyond the molecular diagnostic timeframe and provide insights into the patient's

progression. Such assays also may be used to determine whether titers are maintained over time and thus

the effectiveness of vaccination responses. For example, SARS-CoV-2 vaccine efficacy trials have

highlighted a direct correlation between the titer of antibodies targeting the Receptor Binding Domain

(RBD) found in the S1 subunit of the S protein, the neutralizing antibody titer, and vaccine efficacy[13].

Thus, the development of serological assays targeted to individual SARS-CoV-2 viral antigens could

have important implications for predicting the efficacy of vaccines and estimating the need for boosters.

Molecular diagnostics, on the other hand, commonly involve methods such as quantitative Polymerase

Chain Reaction (qPCR), which require rigorous sample preparation and temperature control, cold storage

of reagents, expensive instrumentation (requiring routine maintenance), and trained personnel to run the

tests. While there are home diagnostic tests approved for use by the U.S. Food and Drug Administration

(FDA), many of these tests either involve self-collection and mailing to a central laboratory or are based

on rapid antigen tests, which have shown to be less accurate than nucleic acid tests, such as qPCR[14].

During the last few years, powerful diagnostic techniques that capitalize on CRISPR (Clustered Regularly

Interspaced Short Palindromic Repeats) technology and associated programmable endonucleases have

gained significant interest, due in part to their high specificity, programmability, and capacity to work at

physiological conditions[15-19]. CRISPR-based diagnostics capitalize on endonucleases, such as Cas12a,

which has a specific cleavage activity towards double-stranded DNA (dsDNA) fragments matching its

guide RNA (gRNA) sequence. Once the Cas12a-gRNA complex binds to its dsDNA target, it activates

and subsequently engages in indiscriminate collateral hydrolysis of nearby single-stranded DNA

(ssDNA)[20,21].

Electrochemical (EC) methods of CRISPR-based nucleic acid detection typically combine nucleic acid

probes conjugated on an electrode with CRISPR Cas effectors and have detection limits in the picomolar-

femtomolar (10^{-12}-10^{-15}) range[22-26]. Unfortunately, those detection limits are inadequate for diagnosing

SARS-CoV-2 in clinical samples, which require ultrasensitive RNA detection at the attomolar (10^{-18})

scale. To overcome this limitation, amplification techniques such as loop-mediated isothermal

amplification (LAMP) can be performed prior to Cas12a detection, which improves the sensitivity of

fluorescent CRISPR-based assays by orders of magnitude[15-17,19,27].

The combination of serological and nucleic acid diagnostics can improve the overall accuracy of SARS-

CoV-2 diagnosis[28] and provide qualitative data on the patient's disease severity and state of progression.

However, workflows for SARS-CoV-2 diagnosis that integrate serological and nucleic acid tests are

currently limited as these assays require laboratory equipment such as pipettes, centrifuges, and heating

blocks, as well as specialized technical skills. Despite the advances to make SARS-CoV-2 tests as widely

available as possible, a lab-on-a-chip (LOC) platform for point-of-care (POC) use that can detect both

SARS-CoV-2 RNA and serological markers is not yet available.

EC biosensors offer a particularly promising solution to achieve ultra-sensitive, selective, multiplexed,

quantitative, and cost-effective LOC detection of both nucleic acids and proteins; they also offer the

potential to interface with electronic medical records, integrated cloud systems, and telemedicine. Despite

their potential, EC diagnostic platforms have only been used to detect either nucleic acid or proteins

individually[26,29] and have been limited to platforms that require multiple liquid handling steps and

specialized equipment. Here, we describe a low-cost, 3D printed, self-contained, LOC diagnostic platform

that is capable of concurrent detection of both SARS-CoV-2 nucleic acids and host antibodies directed

against the virus from unprocessed saliva samples. This device integrates microfluidics that enable

automated liquid handling for sample preparation and a simple and sensitive read-out for both viral RNA

as well as host antibodies. The simplicity of this device makes it user-friendly and should enable its use

for POC testing within hospitals and in COVID-19 testing clinics.

Results

Design of the microfluidic electrochemical lab-on-a-chip platform

In considering the design of an LOC diagnostic device, we focused on accuracy, ease of use, and a

capacity to integrate with digital health platforms. Towards this goal, we fabricated a microfluidic chip

capable of processing untreated saliva to detect both viral RNA and host antibodies on the same EC

sensor chip (**Fig. 1**). We chose saliva over the more common nasopharyngeal swab specimens on our

device due to saliva's ease of self-collection and increased clinical sensitivity due to a high viral load[30,31].

Because unprocessed saliva is viscous and contains nucleases that could inhibit a downstream reaction,

viral RNA is typically purified from saliva using costly and complicated nucleic acid purification kits.

However, to eliminate the need for purification prior to reaction, we experimented with various sample

preparation workflows that would allow for viral lysis and nuclease inactivation (**Supplementary Fig.**

S2). Among different buffers tested, we found that incubating the saliva sample with a Proteinase K[32]

solution at 55ºC followed by a 95ºC inactivation effectively lysed the sample and eliminated false positive

signals without inhibiting the performance of the downstream LAMP and CRISPR-based detection steps.

Following the sample preparation step, we needed a method to capture the nucleic acids from the saliva

sample. We found that a polyethersulfone (PES) membrane was able to concentrate the RNA without

inhibiting the downstream reactions[33-36].

Overall, the device incorporates a 500µL sample preparation chamber which is used for the saliva-based

RNA detection, a 50µL reaction chamber that contains the PES membrane, a 25µL LAMP reservoir, a

22µL CRISPR reservoir, and a 20µL reservoir for direct saliva-based antibody detection. The compact

design allowed for the use of two high-power resistors as heating elements (**Fig. 1b**), one beneath the

sample preparation reservoir and the other beneath the reaction chamber. The LAMP and CRISPR

reservoirs were isolated from the sample preparation reservoir and reaction chamber to assure that there

was no carryover heating from the heated elements during the sample preparation and concentration.

To optimize chip functionality, we tested a variety of reservoir and channel dimensions and placements to

ensure uniform heating and precise fluid flow (**Supplementary Fig. S3**). The chip was designed with

different channel dimensions to establish resistors to the fluid flow while the fluids were controlled by a

small, fingertip-sized DC peristaltic pump with a maximum flow rate of 200 µl/min controlled by an

Arduino microcontroller. The channels leading to the reservoirs were designed with higher resistance to

avoid any backflow or cross-contamination with the reservoirs (400 x 150 µm) (**Supplementary Fig. S4**),

while the ends of the channels leading to the reservoirs were designed with a stepped stop valve to stop

any flow from the reaction chamber to the reservoirs. We tested a variety of reaction chamber geometries

to ensure that the PES membrane surface area was adequate for nucleic acid capture and that the chamber

had optimal fluid retention over the course of the reaction, settling on a serpentine shape (**Supplementary**

Fig. S3) and designed higher resistance on the flow path to the EC sensor chip to avoid unwanted flow

before the desired time point.

The workflow of the sample-to-answer microfluidic detection device with fluid flow driven by an

Arduino-controlled small peristaltic pump is as follows. First, the user manually inputs saliva onto the

antibody detection reservoir (**Fig. 1a**, 5) and the RNA sample preparation reservoir (**Fig. 1a,** 1). In the

RNA sample preparation chamber, the saliva combines with a Proteinase K solution and is heated to 55°C

for 15 mins followed by 95°C for 5 mins using integrated high-power resistors to allow for virus lysis and

nuclease inactivation[32]. The saliva sample is then pumped over the PES membrane within the reaction

chamber, where the RNA binds to the membrane. The reaction chamber is heated to 95°C for an

additional 3-5 min to ensure denaturation of potential reaction inhibitors. The LAMP solution is then

pumped from the reservoir into the reaction chamber and incubated at 65°C for 30 min, followed by the

CRISPR mixture and incubated at 37°C for an additional 30 min, after which it is pumped over the EC

sensor chip to incubate. Saliva for antibody detection is then directly pumped over the EC sensor chip and

incubated. The chip is washed with phosphate buffered saline with Tween® 20 (PBST) followed by the

addition of Polystreptavidin-Horseradish Peroxidase (HRP) and a precipitating form of

tetramethylbenzidine (TMB), after which the chip is read using a potentiostat. A more in-depth visual of

the microfluidic chip and its workflow is provided in **Supplementary Fig. S5**.

Integrated CRISPR-based molecular diagnostic assay

The CRISPR-Cas RNA detection experiments reported here capitalize on Cas12a from *Lachnospiraceae*

bacterium ND2006, which has specific cleavage activity towards dsDNA fragments matching its guide

RNA (gRNA) sequence. Upon target binding, activated Cas12a-gRNA engages in collateral cleavage of

nearby single-stranded DNA (ssDNA)[20,21] that can be read optically as an increase in fluorescence due to

the hydrolysis of a fluorophore-quencher labeled ssDNA reporter. As a result, the signal obtained from

the fluorescent assay will be high in the presence of its SARS-CoV-2 target and low when it is not

detected. LAMP primers[37-41] and Cas12a-gRNAs were evaluated from a range of conserved regions in the

SARS-CoV-2 genome to determine the most sensitive combinations using commercially available,

synthetic full-length SARS-CoV-2 genomic RNA. The ORF1a assay, which targets a highly conserved

region in the SARS-CoV-2 viral genome, had a limit of detection (LOD) of 2.3 viral RNA copies/µL with

a reaction time of 50 min (**Supplementary Table S1, Fig. S6-7**). This LOD is comparable to high-

performance SARS-CoV-2 reverse transcription quantitative polymerase chain reaction (RT-qPCR)

assays[42] with half the time to result. To confirm that the assay was able to detect SARS-CoV-2 active

virus, the ORF1a assay primers and guide RNA were further validated using 11 SARS-CoV-2 RT-qPCR

negative patient saliva samples and 19 SARS-CoV-2 RT-qPCR positive saliva samples with a range of

cycle threshold (C_T) values (**Supplementary Fig. S8-S9, Supplementary Table S2**).

To integrate the CRISPR-based molecular assay onto the EC sensor platform, we designed a biotinylated

ssDNA reporter probe (RP) that partially hybridized to peptide nucleic acid (PNA) capture probes

immobilized on the surface of the antifouling composite-coated gold electrodes[43](**Fig. 2a**). Functionalized

EC biosensors were incubated with samples containing the LAMP/Cas12a mix which includes the

biotinylated ssDNA RP. In the presence of SARS-CoV-2 target RNA, Cas12a collaterally cleaved the

biotinylated ssDNA reporter, leading to a reduction of binding of poly-HRP-streptavidin and thus, a

reduction in the precipitation of TMB deposited locally on the surface of the electrode[43]. Reduced

precipitation of TMB was recorded as peak current, which was measured using cyclic voltammetry (CV)

by sweeping the voltage between -0.5 and 0.5 V (**Fig. 2b**). As a result, the signal obtained from the EC

platform demonstrated an inversely proportional relationship with target concentrations. It should be

noted that the LAMP amplification prior to the CRISPR-based sample detection increases the sensitivity

of the sensor, allowing for a consistently distinguishable signal from samples that are at or above the limit

of detection (LOD) of the sensor (**Fig. 2c**).

To optimize the binding efficiency of the PNA-based CRISPR-EC sensor platform, we varied the

concentration and incubation time of the RP to obtain a rapid, high signal-to-noise ratio (**Supplementary**

Fig. S10-11). Among all the concentrations tested, 1nM RP and 5-min incubation produced a high signal

with no background. Interestingly, the CRISPR-EC sensor platform gave a single molecule LOD of 0.8

cp/µL, which was nearly four times more sensitive than the initial fluorescence-based assays used to

validate the primer and guide pairs (**Supplementary Table S1, Figs. S7 and S12**). To determine the

potential clinical value of the optimized CRISPR-EC sensor platform, we extracted RNA from 19 patient

saliva samples that were positive for SARS-CoV-2 based on RT-qPCR with a range of CT values and 11

RT-qPCR negative clinical saliva samples (**Supplementary Fig. S8**). The current measured in the form

of the output signal from the electrodes was clearly distinguishable (p-value <0.0001) when comparing

the SARS-CoV-2 positive and negative samples (**Fig. 2c**). In addition, ROC curve analysis demonstrated

an impressive correlation with RT-qPCR and CRISPR-based fluorescent detection, with 100% accuracy,

and AUC=1 (**Fig. 2d**).

Multiplexed serology EC assay

Multiplexed assays that diagnose disease by combining viral RNA with serology markers can lead to a

more robust understanding of the progression of diseases, including SARS-CoV-2[44]. The primary

antigens that elicit antibodies during coronavirus infection are the N and S proteins[10]. The N protein is the

most abundant viral protein and is highly conserved among the coronavirus family[45], with several studies

indicating that IgG antibodies targeting the N protein may be more sensitive due to their early appearance

and longer clearance rates during and post-infection[7,11,12]. While the S protein is less conserved than the N

protein, it is highly immunogenic due to the S1 subunit (S1) which mediates attachment to target cells[46].

Studies indicate IgG antibodies against S1 are more specific and strongly correlate with virus

neutralization[47,48]. Antibodies targeting S1 and the ribosomal binding domain within this subunit (S1-

RBD) may also be used to assess the effectiveness of vaccination responses and titer maintenance over

time, with SARS-CoV-2 vaccine efficacy trials highlighting a direct correlation between the titer of

antibodies targeting the RBD of the S protein, the neutralizing antibody titer, and vaccine efficacy[13].

Therefore, to maximize our assay's accuracy, we leveraged the multiplexing capabilities of our EC sensor

and fabricated a multiplexed serology assay capable of measuring antibodies against the S1, S1-RBD, and

N proteins for detection of a patient's immunity, whether through prior viral infection or vaccination.

We began by using an Enzyme-Linked Immunosorbent Assay (ELISA) to optimize the reagents prior to

assembling the multiplexed serology EC sensor chip (**Supplementary Figs. S13-S17**). Initially, a small

set of high-titer and low-titer positive clinical plasma samples were used to optimize the assay over a

broad range of IgG titers. The best performing capture antigens were S1, S1-RBD, and N, and the best

performing detection antibodies were biotinylated goat anti-human IgG, rabbit anti-human IgM, and goat

anti-human IgA. We validated the ELISA accuracy with 58 SARS-CoV-2 plasma samples from patients

with a prior positive SARS-CoV-2 RT-qPCR result and 54 SARS-CoV-2 negative samples. Out of the 54

negative SARS-CoV-2 samples, 22 were collected before the onset of the SARS-CoV-2 pandemic. The

ROC curve analysis of the ELISA results yielded areas under the curve (AUC) between 0.68 and 0.89 for

IgG, IgM and IgA (**Supplementary Figs. S15-S17**).

Next, we used the optimized reagents to develop a multiplexed EC sensor to measure the humoral

response against SARS-CoV-2 from patient plasma samples. We fabricated an EC sensor with an

antifouling coating composed of bovine serum albumin and reduced graphene crosslinked with

glutaraldehyde (BSA/rGOx/GA) [25-27], where each electrode was individually functionalized with S1

(electrode 1), S1-RBD (electrode 2), N (electrode 3), or BSA as an on-chip negative control (electrode 4)

to perform a multi-antigen sandwich EC ELISA (**Fig. 3a**). We used an affinity-based sandwich strategy

for the EC sensor assay, meaning that when SARS-CoV-2 antibodies were present, they bound to both the

surface antigen and secondary antibody, leading to an increase in the EC signal. Each immunoglobulin

isotype (IgG, IgM, IgA) was detected individually on the multiplexed EC sensor chips. **Fig. 3b-e** shows

typical CV results obtained with the multiplexed EC sensor chips for detection of anti-SARS-CoV-2 IgG

using SARS-CoV-2 positive and negative clinical samples.

We optimized the assay conditions of the serology EC assays to obtain the highest signal-to-noise ratios

on both high- and low-titer clinical samples by varying factors such as plasma dilutions, sample

incubation times, and TMB precipitation times (**Supplementary Figs. S18–S20**). We found that a 30-min

sample incubation at a 1:9 plasma dilution with a 3-min TMB precipitation time resulted in the highest

sensitivity and specificity for detection of SARS-CoV-2 antibodies in clinical plasma samples

(**Supplementary Fig. S19c**).

We then evaluated the accuracy of the EC serology platform using plasma samples from patients with a

prior SARS-CoV-2 RT-qPCR positive result. We performed an ROC curve analysis utilizing the 58

SARS-CoV-2 positive plasma samples and 54 SARS-CoV-2 negative samples used to optimize the

ELISA assay (**Fig. 3f, Supplementary S21a**). The clinical samples had a wide range of IgG levels that

were shown to have excellent correlation with our assay (**Supplementary Fig. S22**). Overall, the AUC

for anti-SARS-CoV-2 IgG (**Fig. 3g**) was higher than IgM (**Supplementary S21b**), whereas IgA's AUC

was lowest (between 0.57 and 0.78) and did not add diagnostic value (**Supplementary Fig. S21b**). The

specificity of each individual sensor modified with either S1, N or RBD was over 95% for IgG. Further

analysis of the multiplexed assay's ROC curves showed S1-RBD was the most accurate capture probe

(AUC=1 for IgG), followed by N and S1 (**Fig. 3g, Supplement Fig. S21a**).

In addition, we found that combining the results of the three antigens as a multiplexed readout resulted in

a slight increase in accuracy when assessing a patient's immune status (AUC=1 for IgG) (**Fig. 3f-g,**

combined). The combined EC IgG assay had an excellent correlation with prior SARS-CoV-2 infection

and was shown to be 100% accurate (100% sensitivity and specificity); we therefore used this for

subsequent experiments on the multiplexed EC sensor chips. We also found the EC sensor-based serology

platform to be more accurate in detecting samples from patients with prior SARS-CoV-2 infection than

the ELISA. The high specificity of the EC sensor platform may be attributed to the low non-specific

binding on our nanocomposite-coated EC electrodes[25-27].

A multiplexed viral RNA and antibody diagnostic in a 3D-printed LOC platform

We next worked to combine both EC sensors to create a multiplexed assay for simultaneous viral RNA

and serological biomarker detection on-chip to facilitate increased sensitivity and specificity of SARS-

CoV-2 detection[44]. Saliva is an excellent source of both viral RNA as well as host antibodies (IgG, IgM,

IgA) in SARS-CoV-2 patients[49], and hence is an ideal sample for a multiplexed assay for viral RNA and

serology. Unfortunately, the patient saliva samples used for this study had to be heat-inactivated before

use as saliva from SARS-CoV-2 infected patients are of a highly contagious nature. Because high heat

denatures the antibodies,[1] we spiked a National Institute for Biological Standards and Control (NIBSC)

SARS-CoV-2 IgG calibrant into heat-inactivated saliva samples at 1:20 dilution to simulate the ratio of

IgG present in saliva. After confirming that the signal outputs from the spiked saliva samples were

consistent with the signals generated from the plasma samples (**Supplementary Fig. S23**), we modified

the EC sensor chip so that the four electrodes could be used individually to detect the three antigens (S1,

N, S1-RBD) and PNA (**Fig. 4a**).

To study the performance of our multiplexed EC sensor, we first conducted a two-step assay where

antibody-spiked saliva was split into two volumes: 15µl was incubated on the chip for multiplexed

serological detection of the host's anti-SARS-CoV-2 antibodies and 280µl was used for RNA extraction

followed by the LAMP-CRISPR-based assay and incubation on the same chip. Following incubation of

both samples on the electrodes, we simultaneously measured the SARS-CoV-2 viral RNA and host

antibodies on-chip with the EC sensor readout of precipitating TMB following the addition of poly-HRP

streptavidin. We validated the assay performance by testing the four possible combinations of serology

and RNA-positive and RNA-negative clinical samples (**Supplementary Fig S24**). We achieved a very

high probability (student's t-test p<0.0001) in distinguishing positive from negative samples with an

ultra-low background signal in all the combinations tested. Taken together, these results showed excellent

multiplexing capacity for SARS-CoV-2 viral RNA and host antibodies on the chips with 100%

correlation in specificity and sensitivity.

Following these validation experiments, we integrated the multiplexed EC sensor chip into the compact

LOC microfluidic platform (**Fig. 1)** to test the capabilities for automated viral RNA preparation prior to

the EC sensor readout. Using the same functionalized chip assay as described above, each

clinical saliva sample was split between the RNA and antibody reservoirs and the assay was performed as

described in **Fig. 1a** and **Supplementary Fig. S5**. Similar to the initial validation of the multiplexed

assay, the assay performance of the LOC microfluidic system with integrated EC sensor chip was

validated by testing the four possible combinations of serology and RNA-positive and RNA-negative

clinical samples (**Fig. 4b-e**). Clinical IgG negative samples showed no EC signal for the N, S1 and S1-

RBD antigen-conjugated electrodes (**Fig. 4b, c**), whereas clinical samples from patients exposed to

SARS-CoV-2 showed high IgG loads in all three antigen test areas (student's t-test for S1 and S1-RBD

$p<0.0001$ and for N $p=0.0004$) (**Fig. 4 d, e**). Moreover, we measured high signals on the PNA conjugated

electrode for all clinical samples that were negative for SARS-CoV-2 viral RNA (**Fig. 4b, d)** and low or

no currents on the PNA electrode for SARS-CoV-2 RT-qPCR RNA positive samples (student's t-test

$p=0.0002$) (**Fig. 4 c, e**). Taken together, the results show that the LOC system can effectively prepare and

deliver unprocessed saliva samples containing both SARS-CoV-2 viral RNA and host antibodies for on-

chip simultaneous multiplexed detection with 100% correlation in specificity and sensitivity. A cost

analysis of the LOC multiplexed diagnostic can be seen in **Supplementary Table S4**.

Discussion

Molecular diagnostics for detection of pathogen RNA and serological assays for assessment of host

antibody responses are complementary tools that provide critical information to respond to disease

outbreaks, assess vaccination status, and manage patient care and risks. While molecular diagnostics for

SARS-CoV-2 RNA can be important indicators of viral shedding during the infectious phase of the

disease, sensitivity can vary considerably over the course of the infection. Depending on factors such as

sample types, virus variants, and infection severity[50-55], diagnostics can sometimes detect the presence of

viral RNA long after an infectious phase has subsided,[56] which can complicate patient management and

severely impact society and the economy. Serological assays can provide insights following viral

infection, with antibodies prevalent in a patient's saliva and serum months after infection[1]. Therefore,

combining molecular diagnostics with serological assays can improve accurate monitoring both during

and following an infection.

Multiplexed serology assays combined with nucleic acid assays are increasingly relevant due to the

present level of infection and the current rate of vaccine rollout, which can be used to assess a patient's

response to vaccination[13]. For example, currently available SARS-CoV-2 vaccines induce antibody

production against SARS-CoV-2 S and S1-RBD proteins, and vaccinated individuals who have not been

infected with SARS-CoV-2 are expected to develop measurable antibodies against the S, but not the N

protein[57]. Therefore, multiplexed serology assays that target antibodies against several viral antigens can

become key for seroprevalence studies to estimate the proportion of people in a population that have been

infected, including asymptomatic infection, and/or immunized with vaccines. This information is key to

estimate herd immunity and vaccine efficacy[13], which is critical for the decision to reopen economies[58,59].

In the present study, we described an innovative sample-to-answer diagnostic POC platform that

integrates ultrasensitive and highly specific multiplexed EC sensors within an LOC microfluidic platform,

which can rapidly detect both SARS-CoV-2 viral RNA and antibodies from clinical saliva samples. Due

to its customizable surface chemistry, these EC sensors enable the detection of different targets such as

nucleic acids and proteins. The simple and inexpensive BSA/rGOx/GA-based surface chemistry of the

antifouling sensor coating combined with a poly-HRP streptavidin/TMB output allows for high

conductivity and low nonspecific binding, leading to ultra-low EC background and improved

sensitivity[37,60].

We validated the EC sensor platform for serology and obtained an accuracy of 100% (100% sensitivity

and 100% specificity) for IgG as compared to traditional ELISA, with S1-RBD showing the highest

accuracy in detecting IgG in clinical samples. S1-RBD having the highest accuracy may be explained by

the RBD domain being a highly immunogenic epitope for development of neutralizing antibodies during

the humoral response to SARS-CoV-2[47]. We then characterized a multiplexed EC sensor that detects

antibodies against relevant viral structural proteins (S1-RBD, S1, and N) for a variety of antibody

isotypes (IgG, IgM, and IgA), allowing for a more robust understanding of the humoral response in

patients. Importantly, we also found that simultaneous multiplexed detection of different viral antigens

led to increased diagnostic sensitivity.

We further demonstrated the versatility of our EC sensor platform by performing nucleic acid detection

though a customized molecular assay that builds off of CRISPR-based diagnostics which combines

isothermal nucleic acid amplification with CRISPR-Cas enzymes, such as DETECTR[15] or

SHERLOCK[16,17], to target SARS-CoV-2 viral RNA in saliva. While other CRISPR-Cas diagnostics for

SARS-CoV-2 have been described[61-63], they are typically limited to fluorescence and lateral flow

readouts. In this study, we showed that EC CRISPR diagnostics can detect even more sensitively than

fluorescence-based CRISPR assays using EC sensors, with a similar time to result.

Finally, we designed and tested a novel microfluidic LOC platform that integrates with the multiplexed

EC sensor for simultaneous detection of both RNA and IgG in clinical saliva samples. Saliva is an

excellent alternative to nasopharyngeal swabs and nasal swabs for SARS-CoV-2 diagnosis, as it is simple

to collect, does not require extensive collection equipment, and has been shown to provide both nucleic

acid and serological data during and post infection or vaccination[1,30,64]. We tested the sensor on four

categories of SARS-CoV-2 clinical saliva samples: RNA negative and antibody negative, RNA positive

and antibody positive, RNA negative and antibody positive, and RNA positive and antibody negative.

Clear differentiation was seen between IgG negative and positive samples for N, S1 and S1-RBD antigen-

conjugated electrodes (student's t-test for S1 and S1-RBD $p<0.0001$ and for N $p=0.0004$) as well as

between SARS-CoV-2 viral RNA (student's t-test p=0.0002) within two hours after inputting the

unprocessed saliva sample, highlighting the utility of our platform.

Our LOC microfluidic device, with its low cost and compact design, limits user steps to avoid possible

sources of contamination or human-introduced error to allow for device use by untrained end-users and

further increasing its potential as a POC testing system. A key difference between our work and that of

other recently published POC CRISPR-based electrochemical detection platforms[22-24] is our use of HRP-

TMB for readout, which enables further amplification of the EC signal for both the serological and

CRISPR-based RNA sensors. Importantly, our platform also integrates microfluidics to enable automated

sample preparation, temperature control, and reagent addition steps, thereby creating an easy-to-use

sample-to-answer platform that is more appropriate for POC applications. Novel graphene FET-based EC

biosensors for SARS-CoV-2 have displayed similar levels of sensitivity to the 0.8 ct/µl LOD shown

here[67], but this earlier assay was only validated for VTM-based nasopharyngeal swab samples and more

significantly, it does not have multiplexing capabilities. With our integrated device, we are able to

perform both serological and RNA detection from a saliva sample, which does not require specialized

collection reagents or equipment, and the results are reported concurrently. To our knowledge, this is the

first report of an EC diagnostic device that is multiplexed, highly sensitive, and capable of processing raw

biological samples such as saliva.

Limitations to our study include the small set of clinical COVID-19 saliva samples available due to the

difficulty in acquiring saliva through biorepositories that do not routinely collect this sample type.

However, the fact that we were able to obtain 100% accuracy with clinical samples that contained a wide

range of viral loads strongly suggests that our CRISPR-based EC sensor platform could become a faster,

simpler, and cheaper non-invasive strategy compared to RT-qPCR and traditional fluorescent diagnostics.

Additionally, we are currently implementing a peristaltic pump for fluid movement and a potentiostat for

the readout of the EC sensor chips. While this would not be a limitation to making this multiplexed

diagnostic useful for healthcare and clinical POC settings, it would be difficult for at-home POC use in its

current form. Further work to integrate the electronics and readouts, as well as sourcing recyclable or

biodegradable materials and producing at scale, could allow this device to be affordable and useful into a

home setting.

As the COVID-19 pandemic has shown, there is a critical need to rapidly adapt current testing strategies

to more quickly and easily monitor both the infection and immune status of patients. Knowledge of

infection stages can help curb disease spread, while insights on antibody titer levels can help with

understanding how novel variants may affect individuals with immune protection through infection,

vaccination, or a combination of the two. The streamlined workflow and multiplexing capabilities of our

EC sensor is a step towards building the infrastructure necessary to provide this information to clinicians

and members of the public alike.

Methods

Chip preparation

Gold chips were custom manufactured by Telic Company using a standard photolithography process with

deposition of 15 nm of chromium and 100 nm of gold on a glass wafer. The area of electrodes was

controlled by depositing a layer of 2 µm of insulating layer (SU-8). Prior to use, gold chips were cleaned

by 5-min sonication in acetone (Sigma Aldrich, USA, no. 650501) followed by isopropanol (Sigma

Aldrich, USA, no. W292907). To ensure a clean surface, the chips were then treated with oxygen plasma

using a Zepto Diener plasma cleaner (Diener Electronics, Germany) at 0.5 mbar and 50% power for 2

min.

Nanocomposite preparation and activation

Nanocomposite coating was prepared using the previously described method[43]. Briefly, amine-functional

reduced graphene oxide (Sigma Aldrich, USA, no. 805432) was dissolved in 5 mg/mL BSA (Sigma

Aldrich, USA, no. 05470) in 10 mM PBS solution, pH 7.4 (Sigma Aldrich, USA, no. D8537), and

ultrasonicated for 1 h using 1-s on/off cycles at 50% power. The solution was then denatured by heating

at 105 °C for 5 min and centrifuged to remove the excess aggregates. The nanomaterial solution was then

crosslinked by mixing with 70% glutaraldehyde (Sigma Aldrich, USA, no. G7776) at a ratio of 69:1,

deposited on the glass chip with the gold electrodes and incubated in a humidity chamber for 20-24 h to

form a conductive nanocomposite[65]. After nanocomposite deposition, gold chips were washed in PBS by

agitation (500 rpm) for 10 min and dried with pressurized air. EDC (Thermo Fisher Scientific, USA, no.

22980) and NHS (Sigma Aldrich, USA, no. 130672) were dissolved in 50 mM MES buffer (pH 6.2) at

400 mM and 200 mM, respectively, and deposited on nanocomposite-covered gold chips for 30 min.

After surface activation, chips were quickly rinsed with ultra-pure water and dried, and the capture probes

were spotted on top of the working electrode area.

Clinical samples and ethics statement

De-identified clinical saliva samples from the Dominican Republic were obtained from Boca Biolistics

under their ethical approvals. RT-qPCR was performed by Boca Biolistics using the Perkin Elmer New

Coronavirus Nucleic Acid Detection kit. De-identified clinical plasma samples were obtained from the

Crimson Biomaterials Collection Core Facility at Partners Healthcare (currently Mass General Brigham).

Additional de-identified clinical plasma and saliva samples were obtained through the Massachusetts

Consortium on Pathogen Readiness (MassCPR); these samples had been collected by Prof. Jonathan Li

and Prof. Xu Yu. Additional pre-SARS-CoV-2 pandemic samples were obtained from the Walt

Laboratory at Brigham and Women's Hospital. The Institutional Review Boards at the MGH, MGB, and

Harvard University as well as the Harvard Committee on Microbiological Safety approved the use of the

clinical samples in this study. All clinical samples were inactivated by heating at 65 °C for 30 min prior to

use to denature SARS-CoV-2 virions that might be present in the samples. We extracted total RNA from

saliva via a QIAamp viral RNA mini kit (Qiagen), following manufacturer's instructions and eluted the

total RNA in nuclease-free water.

CRISPR-based RNA assay with fluorescent reporter

CRISPR-based assays require the selection of both LAMP isothermal amplification primers and gRNAs

to detect the LAMP amplicons. LAMP amplification primers (Supplementary Table S3) were selected

after testing a range of LAMP primers, including some from the literature[37-41]. Cas12a gRNAs consist of

two parts: the handle region (UAAUUUCUACUAAGUGUAGAU) that the Cas protein recognizes and

binds, and a user-defined region at the 3' end of the handle that determines the specificity to the target.

Spacer regions were selected following established guidelines[20]. To synthesize the gRNA (gRNA

sequence: UAA UUU CUA CUA AGU GUA GAU GGU GAA ACA UUU GTC ACG CA), synthetic

DNA with an upstream T7 promoter sequence (5′ GAAATTAATACGACTCACTATAGGG 3′) was

purchased from Integrated DNA Technologies (IDT) and in vitro transcribed using the HiScribe T7 High

Yield RNA Synthesis kit from New England Biolabs (NEB). Reactions were incubated for 16 h at 37 °C,

treated with DNase I (NEB), and purified using the RNA Clean & Concentrator-25 kit (ZymoResearch).

gRNA was quantified (ng/μL) on a Nanodrop 2000 (Thermo Fisher Scientific).

Simulated SARS-CoV-2 samples were prepared by serially diluting full-length SARS-CoV-2 viral RNA

(Twist Biosciences, MT106054.1) in nuclease-free water. Viral RNA extracted from saliva samples was

used after purification via the QiAmp viral RNA extraction kit, as explained above. RNA was then

amplified by LAMP and further detected by collateral cleavage of the fluorophore-quenched ssDNA

reporter probe. Briefly, 5 μL of the diluted genomic DNA, or clinical sample RNA extract was added to

2.5 μL of the 10X primer mix (Supplementary Table S3), 12.5 μL of the LAMP master mix (NEB), and 5

μL of water. LAMP mixtures were incubated for 30 min at 65 °C. After LAMP amplification, 4 μL of the

amplified LAMP mixture were mixed with 11 μL of nuclease-free water and 5 μL of the CRISPR

mixture, which contained 1 μM ssDNA fluorophore-quencher reporter (sequence: 6-

FAM/TTATT/IABkFQ), 100 nM Cas, 200 nM gRNA in 10X NEB 2.1 buffer. Reactions were incubated

at 37 °C for 20 min and fluorescence kinetics were measured using a BioTek NEO HTS plate reader

(BioTek Instruments) with readings every 2 min (excitation: 485 nm; emission 528 nm).

Chip functionalization for the CRISPR-based RNA assay with electrochemical reporter

For CRISPR sensors, custom-synthesized amine-terminated peptide nucleic acid (AEEA-

ACAACAACAACAACA) where AEEA is an O-linker was obtained from PNAbio, USA. PNA is a

synthetic analog of DNA with a backbone utilizing repeating units of N-(2-aminoethyl) glycine linked

through amide bonds. PNA contains the same four nucleotide bases as DNA (adenine, cytosine, guanine,

and thymine) but are connected through methylene bridges and a carbonyl group to the central amine of a

peptide backbone[66]. Stock PNA was diluted to 20 µM in 50mM MES buffer and spotted on the working

electrode. One electrode was spotted with 1 mg/mL BSA as a negative control. The spotted chips were

incubated overnight in a humidity chamber. After conjugation, chips were washed and quenched in 1 M

ethanolamine dissolved in 10 mM PBS, pH 7.4 for 30 min and blocked with 1% BSA in 10 mM PBS

containing 0.05% Tween 20.

CRISPR-based RNA assay with electrochemical reporter

The reporter sequence for CRISPR-based EC assays was a ssDNA (sequence: /5Biosg/AT TAT TAT

TAT TAT TTG TTG TTG TTG TTG T) conjugated to a biotin that bound to poly-streptavidin-HRP.

Upon Cas12a activation, the ssDNA-biotin reporter is cleaved in solution, thus preventing binding to the

complementary PNA sequence on the surface. Poly-streptavidin-HRP is then added and able to bind to

the ssDNA reporter-biotin. The concentration of HRP bound to the electrode was read by HRP-dependent

oxidation of precipitating TMB (TMB enhanced one component, Sigma Aldrich, US, no. T9455). TMB

precipitation forms an insulating, non-soluble layer on the electrode surface. Full-length genomic RNA

(Twist Biosciences, MT106054.1) was serially diluted and amplified with 2X LAMP master mix (NEB)

for 30 min at 65 °C. Viral RNA was extracted from saliva via purification with the QiAmp viral RNA

extraction kit. Similar to the protocol explained above, 5 µL of the viral RNA was added to 2.5 µL of the

10X primer mix (Supplementary Table S3), 12.5 µL of the LAMP master mix (NEB), and 5 µL of water.

LAMP mixtures were incubated for 30 min at 65 °C. After LAMP amplification, 4 µL of the amplified

LAMP product was mixed with 10 µL of nuclease-free water and 5 µL of the CRISPR mix, which

contained 4 nM reporter, 100 nM Cas, 200 nM gRNA in 10X NEB 2.1 buffer. Mixtures were incubated

for 20 min at 37 °C, during which time the ssDNA biotinylated reporter was cleaved. After that, 15 µL of

the LAMP/reporter/Cas mixtures was deposited on the chips for 5 min. Thereafter, the chips were washed

and incubated with poly-HRP streptavidin and TMB for 5 min and 1 min, respectively. Final

measurement was then performed in PBST using a potentiostat (Autolab PGSTAT128N, Metrohm; VSP,

Bio-Logic) by a CV scan with 1 V/s scan rate between -0.5 and 0.5 V vs on-chip integrated gold quasi

reference electrode. Peak oxidation current was calculated using Nova 1.11 software. Cyclic voltammetry

allowed us to measure attomolar concentrations of SARS-CoV-2 target RNA.

Serology ELISA assay

ELISA assays were optimized in a 96-well plate format. 100 µL of 1 µg/mL antigens: Spike S1

(SinoBiological, China, no. 40591-V08H), Nucleocapsid (RayBiotech, US, no. 130-10760) and Spike

(S1) RBD (The Native Antigen Company, UK, no. REC31849) were prepared in a 10 mM PBS buffer at

pH 7.4 and added to Nunc™ MaxiSorp™ ELISA plates (BioLegend, no. 423501) and immobilized on the

plates by overnight incubation at 4 °C. The plates were washed three times with 200 µL of PBST

followed by the addition of 250 µL of 5% Blotto for 1 h. After washing the plates, 100 µL of the clinical

plasma samples diluted in 2.5% Blotto was added and incubated for 1h at RT. Plates were further washed

and HRP conjugated anti-human IgA/IgM or biotin-conjugated anti-human IgG detection antibodies were

added for 1h. The secondary antibodies used were: HRP conjugated anti-human IgM (Human IgM mu

chain rabbit Antibody, Rockland, us, no. 109-4107) or IgA (AffiniPure Goat Anti-Human Serum IgA, α

chain specific, Jackson ImmunoResearch, US, no. 109-005-011) or biotin-anti-human IgG (AffiniPure

Goat Anti-Rabbit IgG, Fc fragment specific, Jackson ImmunoResearch, US, no. 111-005-008). The IgG

plate was further mixed with 100µL of Streptavidin-HRP (1:200 dilution in 2.5 % Blotto) and washed.

100 µL of turbo TMB (Thermo Scientific, no. 34022) was added for 20 min followed by the addition of

100 µL of sulfuric acid (0.1M H_2SO_4 in Water) to stop the reaction. The absorbance of the plates was

immediately read using a microplate reader (BioTek NEO HTS plate reader, BioTek Instruments) at 450

nm.

Electrochemical serology assay

To translate the ELISA assays to EC readouts, Spike S1, Nucleocapsid and Spike-RBD were diluted to 1

mg/mL in the PBS buffer and spotted in three electrodes of the EC chip. An additional electrode was

spotted with 1 mg/mL BSA as a negative control. The spotted chips were incubated overnight in a

humidity chamber. After conjugation, chips were washed and quenched in 1 M ethanolamine (Sigma

aldrich, US, no.E9508) dissolved in 10 mM PBS, pH 7.4 for 30 min and blocked with 5% Blotto (Santa

Cruz Biotechnology, US, no. sc-2324) in 10 mM PBS containing 0.05% Tween 20 (Sigma aldrich, US,

no. P9416). The fabricated sensor was then used to detect immunoglobulins from clinical samples. Each

sensor was either used to detect IgG, IgM, or IgA against the three antigens that were immobilized on the

chips. 1.5 µL of clinical plasma samples were mixed with 13.5 µL of 2.5% Blotto and incubated on the

chips for 30 min at RT followed by a rinsing step. After that, HRP conjugated anti-human IgM /IgA/

biotin-anti-human IgG was added for 30 min at RT. 1 µg/mL of poly-HRP-streptavidin

(ThermoScientific, US, no. N200) diluted in 0.1 % BSA in PBST was added to chips with IgG for 5 min.

The chips were rinsed and precipitating TMB was added for 3 min followed by final rinse and EC

measurement using a potentiostat by cyclic voltammograms with a scan rate of 1 V/s between -0.5 and

0.5 V vs on-chip integrated gold quasi reference electrode. Additional antibodies were screened,

including: F(ab')2 Goat anti-Human IgG-Fc Fragment Antibody Biotinylated (Bethyl Laboratories, no.

A80-148B), Goat anti-Human IgG Fc Secondary Antibody, Biotin (ThermoFisher Scientific, US, no.

A18821), Purified anti-human IgG Fc Antibody (BioLegend, no. 409302), Purified anti-human IgG Fc

Antibody (BioLegend, no. 410701), and AffiniPure F(ab')₂ Fragment Goat Anti-Human IgG, Fcγ

fragment specific-biotin (Jackson ImmunoResearch, US, no. 109-006-170).

Multiplexed electrochemical serology and CRISPR-based RNA detection

Multiplexed sensors for both nucleic acid and host antibody detection were prepared by spotting three

electrodes of the EC chip with proteins: Spike S1, Nucleocapsid and Spike-RBD; and spotting the amine-

terminated peptide nucleic acid (AEEA-ACAACAACAACAACA) reporter on the fourth electrode. The

spotted chips were incubated overnight in a humidity chamber. After conjugation, chips were washed and

quenched in 1 M ethanolamine (Sigma aldrich, US, no.E9508) dissolved in 10 mM PBS, pH 7.4 for 30

min and blocked with 1% BSA in 10 mM PBS containing 0.05% Tween 20 (Sigma Aldrich, US, no.

P9416). The fabricated sensor was then used to detect IgG's as well as viral RNA from clinical samples.

Multiplexed chips were used to detect viral RNA as well as IgG against the three antigens that were

immobilized on the EC sensor chips. Negative control saliva (RT-qPCR negative) was heat-inactivated

and spiked with plasma at a ratio of 1:20 to simulate IgG concentrations in saliva. Two experiments were

done in parallel on each chip, as follows: (1) 15µl of plasma-spiked saliva was used for the serology

assays as explained above. Briefly, 0.75 µl of the plasma sample was mixed with 14.25 µl of control

saliva and incubated on the chips for 30 min at RT followed by a rinsing step. After that, biotin-anti-

human IgG was added for 30 min at RT. Chips were then rinsed. (2) In parallel, RNA extracted from RT-

qPCR positive and negative clinical samples was amplified by LAMP for 30min at 65ºC as explained

above. Then, 4 µL of the amplified LAMP product was mixed the CRISPR mix, which contained the

biotinylated reporter and incubated for 20min at 37ºC. 15 µL of the LAMP/reporter/Cas mixtures was

deposited on the chips after the chips had been exposed to SARS-CoV-2 IgG. Thereafter, the chips were

washed and incubated with poly-HRP streptavidin and TMB for 1 min. Final measurement was then

performed in PBST using a potentiostat (Autolab PGSTAT128N, Metrohm; VSP, Bio-Logic) by a CV

scan with 1 V/s scan rate between -0.5 and 0.5 V vs on-chip integrated gold quasi reference electrode.

Peak oxidation current was calculated using Nova 1.11 software. Cyclic voltammetry allowed us to

measure both the presence of IgG antibodies as well as attomolar concentrations of SARS-CoV-2 target

RNA.

Microfluidic chip for multiplexed electrochemical serology and CRISPR-based RNA detection

A microfluidic chip for a point-of-care diagnostic that integrated the multiplexed chip was designed using Autocad software and printed on a Formlabs Form 3B 3D SLA printer in grey resin, Version 4 (Formlabs RS-F2-GPGR-04). The layer thickness chosen for the 3D printing parameters is 50 µm. The chip is cleaned in an isopropanol bath for 20 min, then cured in a heated UV chamber for 1 h at 60°C (Form wash and Form cure, Formlabs). The chip was designed with chambers for saliva, LAMP reagents, and CRISPR reagents, as well as a reaction chamber lined with a PES membrane and a waste port. The PES membrane (Millipore, catalog no. GPWP04700) was laser cut using Epilog Fusion edge 24 laser cutter to fit within the serpentine reaction chamber. The chambers were designed to be connected to the reaction chamber through channels that are closed when under vacuum. Additionally, the chip has a channel and waste port which allow for the integration of the EC sensor chip. The chip was sealed using a clear delayed tack adhesive tape (3M 9795R) to prevent evaporation. Two high-power resistors were used as heating elements for the sample preparation camber and reaction chamber (Digikey 355018RJT) and placed in a custom-printed backing to assure accurate and repeatable heading was provided. A full list of parts along with cost analysis can be found in Supplementary Table S4. The voltages used for each temperature are provided in **Supplementary Fig. S5** and were generated using an Agilent E3631A DC power supply. A complete view of the microfluidic chip can be seen in **Fig. 1** and **Supplementary Fig. S5**. A small DC pump (Takasago RP-Q series) connected to an Arduino Uno was used for the pumping. The workflow for the multiplexed EC assay on the microfluidic chip is as follows: (1) The microfluidic chip was sealed with clear delayed tack adhesive tape. (2) Saliva from patient samples (BioIVT) was inactivated at 95°C for 5 min and mixed with 10% by volume of Proteinase K (NEB P8107S) that was diluted 1:10 in nuclease free water. (3) 450 µL of the saliva mixture was added into the sample preparation chamber and the chamber was heated to 55°C for 15 min, followed by 95°C for 5 min. (4) The sample was pumped over the PES membrane within the reaction chamber at a speed of 50-100µL/min. (5) The reaction chamber was heated to 95°C for 3 min. (6) 25uL of LAMP reaction (12.5 µL

of NEB 2X WarmStart Mastermix, 10 µL of nuclease-free water, and 2.5 µL 10x of LAMP primer mix)

was pumped into the reaction chamber and incubated at 65°C for 30 min. (7) The heat was decreased to

37°C and 22 µL of the Cas mix (15 µL nuclease-free water and 7 µL of the CRISPR mix, which

contained 4 nM reporter, 100 nM Cas, 200 nM gRNA in 10X NEB 2.1 buffer) was pumped into the

reaction chamber and incubated for 30 min. (8) The LAMP/CRISPR reaction was pumped over the EC

sensor chip at 4 µL/min for 5 min followed by 20 µL of PBST at 15 µL/min. (9) 20 µL of saliva sample

spiked with NIBSC antibody calibrant mixed with anti-IgG detection antibody linked with biotin was

flowed through the EC sensor at 4 µL/min for 5 min. (10) The EC sensor chip was washed with 20 µL of

PBST at 15 µL/min followed by addition of 20 µL streptavidin-poly HRP at 6 µL/min. (11) The EC

sensor chip was washed with 20 µL of PBST at 15 µL/min and 20 µL of TMB at 8 µL/min. (12) The EC

sensor chip was washed with 30 µL of PBST at 15 µL/min. (13) The EC sensor chip was read on a

potentiostat and the cyclic voltammogram was generated.

Data analysis

Fluorescence values are reported as absolute values for all experiments used for CRISPR-based

fluorescence assays. Absorbances for the ELISA assays are reported as background-subtracted values to

normalize for plate-to-plate variability. Peak oxidation current for EC CRISPR and serology assays was

calculated using Nova 1.11 software. All data were plotted and statistical tests were performed using

GraphPad Prism 9. Gold standards for ROC curve analysis: the individual samples for both serology and

viral RNA detection were validated using SARS-CoV-2 RT-qPCR. For molecular assays, SARS-CoV-2

positive saliva samples were RT-qPCR positive at the time of saliva collection. For serology assays,

SARS-CoV-2 positive plasma samples were RT-qPCR positive at the time of plasma or at an earlier date.

Receiver operating characteristic (ROC) curves were used to evaluate the performance of diagnostic

assays as a function of the discrimination threshold, plotted as sensitivity (%) versus 100 specificity (%).

The areas under the ROC curve (AUC) are a proxy of test performance, where 1 represents a perfect test

and 0.5 represents a random predictor. ROC curve analysis was done in GraphPad Prism 9 using a 95%

confidence interval and the Wilson/Brown method. Figures were created using Prism 9 and Adobe

Illustrator.

Data availability

All data needed to evaluate the conclusions of this work can be found in the paper and/or the

Supplementary Materials.

Acknowledgements

We would like to thank Tal Gilboa Hitron, Rose A. Lee and Nicole Weckman for helpful discussions and

advice. This work was supported by the Wyss Institute for Biologically Inspired Engineering at Harvard

University and the Paul G. Allen Frontiers Group. J.R. was funded through the UK Natural Environment

Research Council (NERC) GW4 FRESH CDT. H.D.P. was supported by the Harvard University Center

for AIDS Research (CFAR), an NIH-funded program (P30 AI060354), which is supported by the

following NIH co-funding and participating Institutes and Centers: NIAID, NCI, NICHD, NIDCR,

NHLBI, NIDA, NIMH, NIA, NIDDK, NINR, NIMHD, FIC, and OAR. M.Y. acknowledges Fonds de

recherche du Québec nature et technologie (FRQNT) postdoctoral fellowship #260284. The

MGH/MassCPR COVID biorepository was supported by a gift from Ms. Enid Schwartz, by the Mark and

Lisa Schwartz Foundation, the Massachusetts Consortium for Pathogen Readiness, and the Ragon

Institute of MGH, MIT and Harvard.

Author contributions

DN, JR, SS, PJ and HDP share the first author and contributed equally. DN, JR, SS, PJ, HDP, MY, ND,

HS conceived the study under the guidance of JAP, PE, JJC and DEI. Experiments were performed and

validated by DN, JR, SS, PJ, HDP. HDP and PJ formulated the idea, organized the experiments and

managed the project. MY, ND. DRW, GA, JZL, XGY contributed to the collection and characterization

of clinical serum and saliva samples. All authors contributed to manuscript preparation and editing.

Competing interests

HDP, PJ, JJC, DEI are inventors on patents describing the CRISPR EC sensing technology. PJ and DEI

are listed as inventors on patents describing the EC sensor platform. EC sensor platform technology has

been licensed to GBS Inc. for COVID-19 diagnostics and StataDX, Inc.; PJ and DEI hold equity in

StataDx and DEI is a board member. JJC and DRW are co-founders and directors of Sherlock

Biosciences. All other authors declare no competing interests.

References

1. Isho, B.*, et al.* Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. *Science Immunology* **5**, eabe5511 (2020).

2. Wolfel, R.*, et al.* Virological assessment of hospitalized patients with COVID-2019. *Nature* **581**, 465-469 (2020).

3. Pan, Y., Zhang, D.T., Yang, P., Poon, L.L.M. & Wang, Q.Y. Viral load of SARS-CoV-2 in clinical samples. *Lancet Infectious Diseases* **20**, 411-412 (2020).

4. Zou, L.R., *et al.* SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. *New England Journal of Medicine* **382**, 1177-1179 (2020).

5. Gudbjartsson, D.F.*, et al.* Humoral Immune Response to SARS-CoV-2 in Iceland. *New England Journal of Medicine* **383**, 1724-1734 (2020).

6. Gaebler, C.*, et al.* Evolution of antibody immunity to SARS-CoV-2. *Nature* **591**, 639-644 (2021).

7. Van Elslande, J.*, et al.* Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAs. *Clinical Microbiology and Infection* **26**, 1557.e1551-1557.e1557 (2020).

8. Dispinseri, S.*, et al.* Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival. *Nature Communications* **12**, 2670 (2021).

9. Nilsson, A.C.*, et al.* Comparison of six commercially available SARS-CoV-2 antibody assays-Choice of assay depends on intended use. *International Journal of Infectious Diseases* **103**, 381-388 (2021).

10. Fenwick, C.*, et al.* Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies. *Journal of Virology* **95**, e01828-01820 (2021).

11. Manisty, C.*, et al.* Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS-CoV-2 infection. *Ebiomedicine* **65**(2021).

12. Meyer, B., Drosten, C. & Muller, M.A. Serological assays for emerging coronaviruses: Challenges and pitfalls. *Virus Research* **194**, 175-183 (2014).

13. Gilbert, P.B.*, et al.* Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial. *medRxiv*, 2021.2008.2009.21261290 (2021).

14. Mak, G.C.K.*, et al.* Evaluation of rapid antigen test for detection of SARS-CoV-2 virus. *Journal of Clinical Virology* **129**(2020).

15. Chen, J.S.*, et al.* CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. *Science* **360**, 436-439 (2018).

16. Gootenberg, J.S.*, et al.* Nucleic acid detection with CRISPR-Cas13a/C2c2. *Science* **356**, 438-442 (2017).

17. Gootenberg, J.S.*, et al.* Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. *Science* **360**, 439-444 (2018).

18. Lee, R.A.*, et al.* Ultrasensitive CRISPR-based diagnostic for field-applicable detection of Plasmodium species in symptomatic and asymptomatic malaria. *Proceedings of the National Academy of Sciences of the United States of America* **117**, 25722-25731 (2020).

19. Kaminski, M.M.*, et al.* A CRISPR-based assay for the detection of opportunistic infections post-transplantation and for the monitoring of transplant rejection. *Nature Biomedical Engineering* **4**, 601-609 (2020).

20.   Gayet, R.V.*, et al.* Creating CRISPR-responsive smart materials for diagnostics and
programmable cargo release. *Nature Protocols* **15**, 3030-3063 (2020).
21.   English, M.A.*, et al.* Programmable CRISPR-responsive smart materials. *Science* **365**, 780-785
(2019).
22.   Zamani, M.*, et al.* Electrochemical Strategy for Low-Cost Viral Detection. *Acs Central Science* **7**,
963-972 (2021).
23.   Li, F.*, et al.* An ultrasensitive CRISPR/Cas12a based electrochemical biosensor for Listeria
monocytogenes detection. *Biosensors & Bioelectronics* **179**(2021).
24.   Hajian, R.*, et al.* Detection of unamplified target genes via CRISPR–Cas9 immobilized on a
graphene field-effect transistor. *Nature Biomedical Engineering* **3**, 427 – 437 (2019).
25.   Xu, W., Jin, T., Dai, Y.F. & Liu, C.C. Surpassing the detection limit and accuracy of the
electrochemical DNA sensor through the application of CRISPR Cas systems. *Biosensors &
Bioelectronics* **155**, 112100 (2020).
26.   Bruch, R.*, et al.* CRISPR/Cas13a-Powered Electrochemical Microfluidic Biosensor for Nucleic
Acid Amplification-Free miRNA Diagnostics. *Advanced Materials* **31**, 1905311 (2019).
27.   de Puig, H., Bosch, I., Collins, J.J. & Gehrke, L. Point-of-Care Devices to Detect Zika and Other
Emerging Viruses. *Annual Review of Biomedical Engineering* **22**, 371-386 (2020).
28.   Liu, R.*, et al.* Analysis of adjunctive serological detection to nucleic acid test for severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection diagnosis. *International
Immunopharmacology* **86**(2020).
29.   Torrente-Rodriguez, R.M.*, et al.* SARS-CoV-2 RapidPlex: A Graphene-Based Multiplexed
Telemedicine Platform for Rapid and Low-Cost COVID-19 Diagnosis and Monitoring. *Matter*
3(2020).
30.   Wyllie, A.L.*, et al.* Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2.
New England Journal of Medicine **383**, 1283-1286 (2020).
31.   Ott, I.M.*, et al.* Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive
collection devices. *medRxiv*, 2020.2008.2003.20165233 (2020).
32.   Lalli, M.A.*, et al.* Rapid and Extraction-Free Detection of SARS-CoV-2 from Saliva by
Colorimetric Reverse-Transcription Loop-Mediated Isothermal Amplification. *Clinical Chemistry*
67, 415-424 (2021).
33.   Linnes, J.C., Rodriguez, N.M., Liu, L. & Klapperich, C.M. Polyethersulfone improves isothermal
nucleic acid amplification compared to current paper-based diagnostics. *Biomedical Microdevices*
18(2016).
34.   Schlappi, T.S., McCalla, S.E., Schoepp, N.G. & Ismagilov, R.F. Flow-through Capture and in
Situ Amplification Can Enable Rapid Detection of a Few Single Molecules of Nucleic Acids
from Several Milliliters of Solution. *Analytical Chemistry* **88**, 7647-7653 (2016).
35.   Rodriguez, N.M.*, et al.* Paper-Based RNA Extraction, in Situ Isothermal Amplification, and
Lateral Flow Detection for Low-Cost, Rapid Diagnosis of Influenza A (H1N1) from Clinical
Specimens. *Analytical Chemistry* **87**, 7872-7879 (2015).
36.   de Puig, H.*, et al.* Minimally instrumented SHERLOCK (miSHERLOCK) for CRISPR-based
point-of-care diagnosis of SARS-CoV-2 and emerging variants. *Science Advances* **7**, eabh2944
(2021).

37.   Rabe, B.A. & Cepko, C. SARS-CoV-2 detection using isothermal amplification and a rapid,
inexpensive protocol for sample inactivation and purification. *Proceedings of the National*
Academy of Sciences of the United States of America **117**, 24450-24458 (2020).
38.   Lu, R.F.*, et al.* Development of a Novel Reverse Transcription Loop-Mediated Isothermal
Amplification Method for Rapid Detection of SARS-CoV-2 (vol 18, pg 615, 2020). *Virologica*
Sinica **35**, 499-499 (2020).
39.   Rohaim, M.A.*, et al.* Artificial Intelligence-Assisted Loop Mediated Isothermal Amplification
(AI-LAMP) for Rapid Detection of SARS-CoV-2. *Viruses-Basel* **12**(2020).
40.   Nawattanapaiboon, K.*, et al.* Colorimetric reverse transcription loop-mediated isothermal
amplification (RT-LAMP) as a visual diagnostic platform for the detection of the emerging
coronavirus SARS-CoV-2. *Analyst* **146**, 471-477 (2021).
41.   Yan, C.*, et al.* Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse
transcription loop-mediated isothermal amplification assay. *Clinical Microbiology and Infection*
26, 773-779 (2020).
42.   FDA. CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel (CDC) - Manufacturer
Instructions/Package Insert | FDA, (available at https://www.fda.gov/media/134922/download).
43.   Zupancic, U., Jolly, P., Estrela, P., Moschou, D. & Ingber, D.E. Graphene Enabled Low-Noise
Surface Chemistry for Multiplexed Sepsis Biomarker Detection in Whole Blood. *Advanced*
Functional Materials **31**, 2010638 (2021).
44.   Ter-Ovanesyan, D.*, et al.* Ultrasensitive Measurement of Both SARS-CoV-2 RNA and
Antibodies from Saliva. *Analytical Chemistry* **93**, 5365-5370 (2021).
45.   Satarker, S. & Nampoothiri, M. Structural Proteins in Severe Acute Respiratory Syndrome
Coronavirus-2. *Archives of Medical Research* **51**, 482-491 (2020).
46.   Huang, Y., Yang, C., Xu, X.F., Xu, W. & Liu, S.W. Structural and functional properties of
SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. *Acta*
Pharmacologica Sinica **41**, 1141-1149 (2020).
47.   Premkumar, L.*, et al.* The receptor-binding domain of the viral spike protein is an
immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. *Science*
Immunology **5**, eabc8413 (2020).
48.   Amanat, F.*, et al.* A serological assay to detect SARS-CoV-2 seroconversion in humans. *Nature*
Medicine **26**, 1033-+ (2020).
49.   Sterlin, D.*, et al.* IgA dominates the early neutralizing antibody response to SARS-CoV-2.
Science Translational Medicine **13**(2021).
50.   Zohar, T.*, et al.* Compromised Humoral Functional Evolution Tracks with SARS-CoV-2
Mortality. *Cell* **183**, 1508-1519 (2020).
51.   Yurkovetskiy, L.*, et al.* Structural and Functional Analysis of the D614G SARS-CoV-2 Spike
Protein Variant. *Cell* **183**, 739-751 (2020).
52.   Calistri, P.*, et al.* Infection sustained by lineage B.1.1.7 of SARS-CoV-2 is characterised by
longer persistence and higher viral RNA loads in nasopharyngeal swabs. *International Journal of*
Infectious Diseases **105**, 753-755 (2021).
53.   Fajnzylber, J.*, et al.* SARS-CoV-2 viral load is associated with increased disease severity and
mortality. *Nature Communications* **11**, 5493 (2020).

54.   van Kampen, J.J.A.*, et al.* Duration and key determinants of infectious virus shedding in
hospitalized patients with coronavirus disease-2019 (COVID-19). *Nature Communications* **12**,
267 (2021).

55.   Golubchik, T.*, et al.* Early analysis of a potential link between viral load and the N501Y mutation
in the SARS-COV-2 spike protein. *medRxiv*, 2021.2001.2012.20249080 (2021).

56.   Qu, Y.M., Kang, E.M. & Cong, H.Y. Positive result of Sars-Cov-2 in sputum from a cured
patient with COVID-19. *Travel Medicine and Infectious Disease* **34**(2020).

57.   Dörschug, A.*, et al.* Comparative Assessment of Sera from Individuals after S-Gene RNA-Based
SARS-CoV-2 Vaccination with Spike-Protein-Based and Nucleocapsid-Based Serological
Assays. *Diagnostics (Basel)* **11**, 426 (2021).

58.   Ndaye, A.N., Hoxha, A. & Madinga, J. Challenges in interpreting SARS-CoV-2 serological
results in African countries (vol 9, pg E588, 2021). *Lancet Global Health* **9**, E597-E597 (2021).

59.   Schaffer DeRoo, S., Pudalov, N.J. & Fu, L.Y. Planning for a COVID-19 Vaccination Program.
Jama-Journal of the American Medical Association **323**, 2458-2459 (2020).

60.   Timilsina, S.S.*, et al.* Rapid antifouling nanocomposite coating enables highly sensitive
multiplexed electrochemical detection of myocardial infarction and concussion markers.
medRxiv, 2021.2006.2013.21258856 (2021).

61.   Broughton, J.P.*, et al.* CRISPR-Cas12-based detection of SARS-CoV-2. *Nature Biotechnology*
38, 870-874 (2020).

62.   Rauch, J.N.*, et al.* A Scalable, Easy-to-Deploy Protocol for Cas13-Based Detection of SARS-
CoV-2 Genetic Material. *Journal of Clinical Microbiology* **59**, e02402-02420 (2021).

63.   Arizti-Sanz, J.*, et al.* Streamlined inactivation, amplification, and Cas13-based detection of
SARS-CoV-2. *Nature Communications* **11**, 5921 (2020).

64.   Lee, R.A., Herigon, J.C., Benedetti, A., Pollock, N.R. & Denkinger, C.M. Performance of Saliva,
Oropharyngeal Swabs, and Nasal Swabs for SARS-CoV-2 Molecular Detection: a Systematic
Review and Meta-analysis. *Journal of Clinical Microbiology* **59**, e02881-02820 (2021).

65.   del Rio, J.S., Henry, O.Y.F., Jolly, P. & Ingber, D.E. An antifouling coating that enables affinity-
based electrochemical biosensing in complex biological fluids. *Nature Nanotechnology* **14**, 1143-
1149 (2019).

66.   Jolly, P., Rainbow, J., Regoutz, A., Estrela, P. & Moschou, D. A PNA-based Lab-on-PCB
diagnostic platform for rapid and high sensitivity DNA quantification. *Biosensors &*
Bioelectronics **123**, 244-250 (2019).

67.   Wang, L., Wang, X., Wu, Y., Guo, M., Gu, C., Dai, C., Kong, D., Wang, Y., Zhang, C., Qu, D.
and Fan, C. Rapid and ultrasensitive electromechanical detection of ions, biomolecules and SARS
CoV-2 RNA in unamplified samples. *Nature Biomedical Engineering*, pp.1-10 (2022).

Figures

851
Fig 1: Overview of multiplexed electrochemical sensor system. (a) Overview of the microfluidic chip

designed for an LOC sample-to-answer saliva detection of SARS-CoV-2 RNA and antibodies. (1) The user

inputs saliva onto the antibody detection reservoir and a saliva and proteinase K mixture into the sample

preparation reservoir, where it incubates. (2) The saliva is pumped over the PES membrane inside the

reaction chamber for RNA capture and heated to denature potential reaction inhibitors. (3) The LAMP

solution is then pumped from the reservoir into the reaction chamber and incubated. (4) The CRISPR

mixture is pumped into the reaction chamber, incubated and then pumped over the EC sensor chip. (5)

The saliva for antibody detection is pumped over the EC sensor chip. (6) After the addition of

polystreptavidin-HRP and TMB, results from the EC sensor chip are read with a potentiostat. (b) An

exploded view of the multiplexed system, which includes a heater system, a sealed microfluidic chip, and

a multiplexed EC sensor chip. (c) Photograph of the microfluidic system with a quarter dollar for scale.

863
864

Fig. 2. Schematic of the CRISPR electrochemical assays and assay performance using clinical

samples. (a) Schematic illustrating the surface chemistry of the EC assay. Without viral RNA present, the

biotinylated ssDNA reporter probe is not cleaved; therefore, the poly-HRP streptavidin binds to the

PNA/biotin-DNA duplex when added to the EC sensor chip and consequently precipitates TMB resulting

in an increase in current. In contrast, the biotinylated reporter ssDNA is hydrolyzed in the presence of

viral target RNA, cleaving the biotin group. Consequently, poly-HRP streptavidin does not bind to the

surface of the chips, resulting in no TMB precipitation and no increase in current. (b) Cyclic

voltammogram showing the typical current peak signal achieved after incubation of samples from both

SARS-CoV-2 negative (orange) and positive (blue) clinical samples. (c) Clinical samples that contained

SARS-CoV-2 viral RNA (+, blue) had low signals in our device and were clearly distinguishable from the

high signals obtained for samples that did not contain viral RNA (-, orange). Student's t-test p value

<0.001 (***). (d) Summary table listing the numerical values of the receiver operating characteristic

(ROC) curve analysis of the patient sample data collected for the SARS CoV-2 assay. The table shows a

summary of the results from 19 RT-qPCR confirmed positive and 10 negative human saliva samples.

AUC: area under the curve; 95% conf. Int.: 95% confidence interval; Sens: sensitivity; Spec.: specificity;

N pos.: number of RT-qPCR SARS-CoV-2 positive samples; N neg.: number of RT-qPCR SARS-CoV-2

negative clinical samples.

***Fig. 3: Schematic and representative raw cyclic voltammetry data of the multiplexed serology assay.** (a)*

Schematic illustrating the multiplexed EC serological assay to assess host antibody responses on

electrodes functionalized with SARS-CoV-2 antigens. Host antibodies bind to the SARS-CoV-2 antigens

immobilized on the chips. Subsequently, biotinylated anti-human IgG secondary antibodies bind, followed

by poly HRP-streptavidin binding and TMB precipitation on the chips. (b-e) Typical cyclic

voltammograms for the four different electrodes that target host antibodies against (b) Spike 1 subunit

(S1), (c) Spike 1-receptor binding domain (S1-RBD), (d) nucleocapsid (N), and (e) BSA negative control

(f) ROC curves generated from the patient sample data obtained for the IgG EC serology assay. (g) Table

listing the numerical values of the sensitivity and specificity results. AUC: area under the curve; 95%

conf. Int.: 95% confidence interval; Sens: sensitivity; Spec.: specificity; N pos.: number of gold standard

SARS-CoV-2 positive samples; N neg.: number of gold standard SARS-CoV-2 negative clinical samples.

Fig. 4. Electrochemical platforms can be used for multiplexed sensing with simultaneous detection of

SARS-CoV-2 viral RNA and host antibodies against the virus. *(a) Schematic of the multiplexed chip*

surface conjugated with SARS-CoV-2 antigens: Spike (S1), S1-Receptor binding domain (S1-RBD), and

Nucleocapsid (N); as well as peptide nucleic acid (PNA) for the detection of SARS-CoV-2 viral RNA on

the LOC microfluidic system. (b-e) Current (A) EC readout from the LOC microfluidic chip for clinical

samples containing different host antibody and viral RNA combinations: (b) Clinical samples negative for

both serology and viral RNA. (c) Clinical samples with negative host antibody levels and positive for viral

RNA. (d) Clinical samples that contain host antibodies against SARS-CoV-2 but are negative for viral

RNA. (e) Clinical samples with both positive host antibodies and viral RNA.

909